PRIORITETI U ZDRAVSTVU I RIJETKE MALIGNE BOLESTI. ORFAN TERAPIJA KOD BRCA 1,2 MUTIRANOG RAKA JAJNIKA. ISKUSTVO IZ CRNE GORE

  • Nada Cicmil-Sarić Cicmil-Sarić Nada, MD Senior Medical Advisor Authorised Doctor of French Embassy in Montenegro Clinic for Oncology and Radiotherapy Clinical Center of Montenegro Ljubljanska b.b. Podgorica, Montenegro

Sažetak


Rak jajnika nije najčešći, ali izvjesno predstavlja najsmrtonosniji ginekološki tumor.
Nove molekularno genetske studije, dijele rak jajnika na tip 1 i tip 2. Podtip 2 seroznog
papilarnog raka jajnika visokog gradusa je dominantan, agresivan i prouzrokuje 70-80% umiranja
od ukupnog broja žena. U smislu terapijskog odgovora, rak jajnika se dijeli na platina senzitivni i
platina rezistentni. Savremeni tretman održavanja postignutog terapijskog odgovora kod
rekurentne bolesti koja odgovara na liječenje derivatima platine a koja je BRCA 1, 2 mutirana, je
primjena PARP inhibitora. EMA je odobrila primjenu jedne vrste PARP inhibitora iz grupe orfan
lijekova za ovu indikaciju. Prikazujemo dva slučaja i analiziramo način na koji se u zemljama u
razvoju u koje spade i Crna Gora, obezbjeđuje najsavremeniji tretman za ove pacijentkinje.

Ključne riječi: rak jajnika, BRCA 1, 2 mutiran, rijetka bolest, PARP inhibitori

Biografija autora

Nada Cicmil-Sarić, Cicmil-Sarić Nada, MD Senior Medical Advisor Authorised Doctor of French Embassy in Montenegro Clinic for Oncology and Radiotherapy Clinical Center of Montenegro Ljubljanska b.b. Podgorica, Montenegro
Cicmil-Sarić Nada, MD
Senior Medical Advisor
Authorised Doctor of French Embassy in Montenegro
Clinic for Oncology and Radiotherapy Clinical Center
of Montenegro
Ljubljanska b.b. Podgorica, Montenegro

Reference

Michael-Antony Lisio, Lili Fu, Alicia Goyeneche, Zu-hua Gao and Carlos Telleria. High-

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA

Ferlay J, Soerjomataram I, Dikshit R etal. Cancer incidence and mortality worldwide:

Kurman, RJ, Carcangiu ML, Herrington CS, Young RH. WHO Classification of Tumours

Shih Ie, M, Kurman RJ. Ovarian tumorigenesis: A proposed model based on

Lengyel, E. Ovarian cancer development and metastasis. Am. J. Pathol. 2010, 177,

Bowtell DD, Böhm S, Ahmed AA. etal. Rethinking ovarian cancer II: Reducing mortality

Daniela Luvero, Andrea Milani, and Jonathan A. Lederman. Treatment options in

http://www.checkorphan.org/diseases/?b_start:int=200&letter=O

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2009/11/

https.//www.ncbi.nim. nih.gov/pmc/articles/PMC5522225

Ohmoto A, Yachida S. Current status of poly (ADP-ribose) polymerase inhibitors and

Bitler BG, Watson ZL, Wheeler LJ, Behbakht K. PARP inhibitors: Clinical utility and

Meinhold-Heerlein I, Fotopoulou C, Harter P etal.. The new WHO classification of

Malignant neoplasms in Montenegro 2013. Podgorica: Insitute of Public Health of

NCI: Recurrent and persistent ovarian epithelial cancer treatment,

Schrader KA, Hurlburt J, Kalloger SE etal. Germline BRCA1 and BRCA2 mutations in

Friedlander M, Trimble E, Tinker A, Alberts D etal.Gynecologic Cancer InterGroup.

Kathryn Alsop, Sian Fereday, Cliff Meldrum etal. BRCA Mutation Frequency and

TCGA The Cancer Genome Atlas Network. Comprehensive molecular portraits of human

Burgess M and Puhalla S. BRCA 1/2-mutation related and sporadic breast and ovarian

Objavljeno
2020/02/03
Rubrika
Iskustva iz prakse